Patents by Inventor Stuart Travers
Stuart Travers has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240140908Abstract: The present invention relates to (R)-4-[5-(4-chlorophenyl)-1-[2-(trifluoromethyl)-phenyl]pyrrol-2-yl]-N-[2-(dimethylamino)-ethyl]benzamide (+)-L-tartrate salt, methods for its preparation, pharmaceutical compositions containing it and its use in treating diseases such as cancer.Type: ApplicationFiled: September 23, 2021Publication date: May 2, 2024Applicant: SENTINEL ONCOLOGY LIMITEDInventors: Meriel Ruth MAJOR, Robert George BOYLE, Stuart TRAVERS, David Winter WALKER, Julian Scott NORTHEN, Stefania SANTONI
-
Publication number: 20240083906Abstract: This invention relates to compounds and methods for the treatment of cancer. In particular, the invention provides compounds that inhibit Aurora kinase, pharmaceutical compositions comprising the compounds, and methods of using the compounds for the treatment of cancer.Type: ApplicationFiled: October 19, 2023Publication date: March 14, 2024Inventors: Christopher F. Claiborne, Lloyd J. Payne, Richard J. Boyce, Todd B. Sells, Stephen G. Stroud, Stuart Travers, Tricia J. Vos, Gabriel S. Weatherhead
-
Publication number: 20220348565Abstract: The invention provides a composition of matter which: (i) consists of at least 90% by weight of an atropisomer (2A) and 0-10% by weight of an atropisomer of formula (2B); or (ii) consists of at least 90% by weight of an atropisomer (2B) and 0-10% by weight of an atropisomer of formula (2A); wherein the atropisomer of formula (2A) and the atropisomer of formula (2B) are represented by: or are pharmaceutically acceptable salts or tautomers thereof, wherein ring X is a benzene or pyridine ring; ring Y is selected from a benzene ring, a pyridine ring and a thiophene ring; R1 is trifluoromethyl; R2 is hydrogen; R3 is hydrogen; m is 0 or 1; n is 0, 1 or 2; Ar1 is a monocyclic aromatic ring selected from benzene and pyridine; each monocyclic aromatic ring being unsubstituted or substituted with 1 or 2 substituents R5 as defined herein; and R4; R5 when present, R6 and R7 independently selected from various substituents as defined herein.Type: ApplicationFiled: September 25, 2020Publication date: November 3, 2022Applicant: SENTINEL ONCOLOGY LIMITEDInventors: Robert George BOYLE, Meriel Ruth MAJOR, Stuart TRAVERS, David Winter WALKER, Michal CZYZEWSKI, Derek John LONDESBROUGH, Julian Scott NORTHEN, Stefania SANTONI
-
Publication number: 20220041605Abstract: This invention relates to compounds and methods for the treatment of cancer. In particular, the invention provides compounds that inhibit Aurora kinase, pharmaceutical compositions comprising the compounds, and methods of using the compounds for the treatment of cancer.Type: ApplicationFiled: May 24, 2021Publication date: February 10, 2022Inventors: Christopher F. Claiborne, Lloyd J. Payne, Richard J. Boyce, Todd B. Sells, Stephen G. Stroud, Stuart Travers, Tricia J. Vos, Gabriel S. Weatherhead
-
Patent number: 11014928Abstract: This invention relates to compounds and methods for the treatment of cancer. In particular, the invention provides compounds that inhibit Aurora kinase, pharmaceutical compositions comprising the compounds, and methods of using the compounds for the treatment of cancer.Type: GrantFiled: September 13, 2019Date of Patent: May 25, 2021Assignee: Millennium Pharmaceuticals, Inc.Inventors: Christopher F. Claiborne, Lloyd J. Payne, Richard J. Boyce, Todd B. Sells, Stephen G. Stroud, Stuart Travers, Tricia J. Vos, Gabriel S. Weatherhead
-
Publication number: 20200247810Abstract: This invention relates to compounds and methods for the treatment of cancer. In particular, the invention provides compounds that inhibit Aurora kinase, pharmaceutical compositions comprising the compounds, and methods of using the compounds for the treatment of cancer.Type: ApplicationFiled: September 13, 2019Publication date: August 6, 2020Inventors: Christopher F. Claiborne, Lloyd J. Payne, Richard J. Boyce, Todd B. Sells, Stephen G. Stroud, Stuart Travers, Tricia J. Vos, Gabriel S. Weatherhead
-
Patent number: 10414770Abstract: This invention relates to compounds and methods for the treatment of cancer. In particular, the invention provides compounds that inhibit Aurora kinase, pharmaceutical compositions comprising the compounds, and methods of using the compounds for the treatment of cancer.Type: GrantFiled: September 18, 2017Date of Patent: September 17, 2019Assignee: Millennium Pharmaceuticals, Inc.Inventors: Christopher F. Claiborne, Lloyd J. Payne, Richard J. Boyce, Todd B. Sells, Stephen G. Stroud, Stuart Travers, Tricia J. Vos, Gabriel S. Weatherhead
-
Publication number: 20180134716Abstract: This invention relates to compounds and methods for the treatment of cancer. In particular, the invention provides compounds that inhibit Aurora kinase, pharmaceutical compositions comprising the compounds, and methods of using the compounds for the treatment of cancer.Type: ApplicationFiled: September 18, 2017Publication date: May 17, 2018Inventors: Christopher F. Claiborne, Lloyd J. Payne, Richard J. Boyce, Todd B. Sells, Stephen G. Stroud, Stuart Travers, Tricia J. Vos, Gabriel S. Weatherhead
-
Patent number: 9765078Abstract: This invention relates to compounds and methods for the treatment of cancer. In particular, the invention provides compounds that inhibit Aurora kinase, pharmaceutical compositions comprising the compounds, and methods of using the compounds for the treatment of cancer.Type: GrantFiled: July 27, 2015Date of Patent: September 19, 2017Assignee: Millennium Pharmaceuticals, Inc.Inventors: Christopher F. Claiborne, Lloyd J. Payne, Richard J. Boyce, Todd B. Sells, Stephen G. Stroud, Stuart Travers, Tricia J. Vos, Gabriel S. Weatherhead
-
Publication number: 20160185782Abstract: This invention relates to compounds and methods for the treatment of cancer. In particular, the invention provides compounds that inhibit Aurora kinase, pharmaceutical compositions comprising the compounds, and methods of using the compounds for the treatment of cancer.Type: ApplicationFiled: July 27, 2015Publication date: June 30, 2016Inventors: Christopher F. Claiborne, Lloyd J. Payne, Richard J. Boyce, Todd B. Sells, Stephen G. Stroud, Stuart Travers, Tricia J. Vos, Gabriel S. Weatherhead
-
Patent number: 9102678Abstract: This invention relates to compounds and methods for the treatment of cancer. In particular, the invention provides compounds that inhibit Aurora kinase, pharmaceutical compositions comprising the compounds, and methods of using the compounds for the treatment of cancer.Type: GrantFiled: October 3, 2012Date of Patent: August 11, 2015Assignee: Millennium Pharmaceuticals, Inc.Inventors: Christopher F. Claiborne, Lloyd J. Payne, Richard J. Boyce, Todd B. Sells, Stephen G. Stroud, Stuart Travers, Tricia J. Vos, Gabriel S. Weatherhead
-
Patent number: 8399659Abstract: This invention relates to compounds and methods for the treatment of cancer. In particular, the invention provides compounds that inhibit Aurora kinase, pharmaceutical compositions comprising the compounds, and methods of using the compounds for the treatment of cancer.Type: GrantFiled: May 27, 2009Date of Patent: March 19, 2013Assignee: Millennium Pharmaceuticals, Inc.Inventors: Christoper F. Claiborne, Lloyd J. Payne, Richard J. Boyce, Todd B. Sells, Stephen G. Stroud, Stuart Travers, Tricia J. Vos, Gabriel S. Weatherhead
-
Publication number: 20100048540Abstract: The invention relates to novel heterocyclic N-oxides which are useful as hypoxic selective cytotoxic agents that mediate and/or inhibit cell proliferation, for example, through the activity of protein kinases. The invention is further related to pharmaceutical compositions containing such compounds and compositions, and to methods of treating cancer as well as other disease states associated with unwanted ahgiogenesis and/or cellular proliferation by administering effective amounts of such compounds.Type: ApplicationFiled: February 1, 2006Publication date: February 25, 2010Applicant: SENTINEL ONCOLOGY LIMITEDInventors: Robert George Boyle, Stuart Travers
-
Publication number: 20090299060Abstract: This invention relates to compounds and methods for the treatment of cancer. In particular, the invention provides compounds that inhibit Aurora kinase, pharmaceutical compositions comprising the compounds, and methods of using the compounds for the treatment of cancer.Type: ApplicationFiled: May 27, 2009Publication date: December 3, 2009Applicant: Millennium Pharmaceuticals, Inc.Inventors: Christopher F. Claiborne, Lloyd J. Payne, Richard J. Boyce, Todd B. Sells, Stephen G. Stroud, Stuart Travers, Tricia J. Vos, Gabriel S. Weatherhead
-
Publication number: 20090270416Abstract: The invention provides a Chk-1 kinase inhibiting compound of the formula (I) or a salt, solvate or tautomer thereof, wherein: G is CH2, O, NH, NHCO or CONH; A is a group (CH2)n where n is 1 to 4 provided that when G is O or NH, n is at least 2; X1 is nitrogen or CH; X2 is nitrogen or a group CR5; X3 is nitrogen or a group CR5; X4 is nitrogen or CH; provided that no more than two of X2, X3 and X4 are nitrogen; and R1; R2; R3; R4; R5 and R6 are as defined in the claims.Type: ApplicationFiled: June 8, 2007Publication date: October 29, 2009Applicant: SENTINEL ONCOLOGY LIMITEDInventors: Robert George Boyle, Stuart Travers
-
Patent number: 7572784Abstract: This invention relates to compounds and methods for the treatment of cancer. In particular, the invention provides compounds that inhibit Aurora kinase, pharmaceutical compositions comprising the compounds, and methods of using the compounds for the treatment of cancer.Type: GrantFiled: May 12, 2005Date of Patent: August 11, 2009Assignee: Millennium Pharmaceuticals, Inc.Inventors: Christopher F. Claiborne, Lloyd J. Payne, Richard J. Boyce, Todd B. Sells, Stephen G. Stroud, Stuart Travers, Tricia J. Vos, Gabriel S. Weatherhead
-
Publication number: 20080234276Abstract: The invention relates to novel heterocyclic triazines which are useful as hypoxic selective cytotoxic agents that mediate and/or inhibit cell proliferation, for example, through the activity of protein kinases. The invention is further related to pharmaceutical compositions containing such compounds and compositions, and to methods of treating cancer as well as other disease states associated with unwanted angiogenesis and/or cellular proliferation by administering effective amounts of such compounds.Type: ApplicationFiled: February 1, 2006Publication date: September 25, 2008Applicant: SENTINEL ONCOLOGY LIMITEDInventors: Robert George Boyle, Stuart Travers
-
Publication number: 20070185087Abstract: This invention relates to compounds and methods for the treatment of cancer. In particular, the invention provides compounds that inhibit Aurora kinase, pharmaceutical compositions comprising the compounds, and methods of using the compounds for the treatment of cancer.Type: ApplicationFiled: December 21, 2006Publication date: August 9, 2007Applicant: Millennium Pharmaceuticals, Inc.Inventors: Christoper Claiborne, Lloyd Payne, Richard Boyce, Todd Sells, Stephen Stroud, Stuart Travers, Tricia Vos, Gabriel Weatherhead
-
Publication number: 20050256102Abstract: This invention relates to compounds and methods for the treatment of cancer. In particular, the invention provides compounds that inhibit Aurora kinase, pharmaceutical compositions comprising the compounds, and methods of using the compounds for the treatment of cancer.Type: ApplicationFiled: May 12, 2005Publication date: November 17, 2005Applicant: Millennium Pharmaceuticals, Inc.Inventors: Christopher Claiborne, Lloyd Payne, Richard Boyce, Todd Sells, Stephen Stroud, Stuart Travers, Tricia Vos, Gabriel Weatherhead